The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention

Clinical Science

Volumn 128, Issue 2, 2015, Pages 121-130

  Siller Matula, Jolanta M ^a   Gruber, Carina ^b   Francesconi, Marcel ^b   Dechant, Cornelia ^b   Jilma, Bernd ^a   Delle Karth, Georg ^a   Grohs, Katharina ^b   Podczeck Schweighofer, Andrea ^b   Christ, Günter ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Acute coronary syndrome; Blood platelet; Clopidogrel; Haemorrhage; Thrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEATED DRUG DOSE; RISK FACTOR; STENT THROMBOSIS; THERAPEUTIC INDEX; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT RESPONSE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS;

AGED; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; REGRESSION ANALYSIS; THIOPHENES; TICLOPIDINE;

EID: 84921680241     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20140310     Document Type: Article

References (50)

1. Tantry, U. S., Bonello, L., Aradi, D., Price, M. J., Jeong, Y. H., Angiolillo, D. J., Stone, G. W., Curzen, N., Geisler, T., Ten Berg, J. et al. (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62, 2261-2273
2. Siller-Matula, J. M., Trenk, D., Schror, K., Gawaz, M., Kristensen, S. D., Storey, R. F., Huber, K. and EPA (2013) Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc. Interv. 6, 1111-1128
3. Siller-Matula, J. M., Trenk, D., Schror, K., Gawaz, M., Kristensen, S. D., Storey, R. F., Huber, K. and EPA (2014) How to improve the concept of individualized antiplatelet therapy with P2Y12 receptor inhibitors - is an algorithm the answer? Thromb. Haemost., in the press
4. von Beckerath, N., Kastrati, A., Wieczorek, A., Pogatsa-Murray, G., Sibbing, D., Graf, I. and Schomig, A. (2007) A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur. Heart J. 28, 1814-1819
5. Angiolillo, D. J., Bernardo, E., Sabate, M., Jimenez-Quevedo, P., Costa, M. A., Palazuelos, J., Hernandez-Antolin, R., Moreno, R., Escaned, J., Alfonso, F. et al. (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J. Am. Coll. Cardiol. 50, 1541-1547
6. Angiolillo, D. J., Bernardo, E., Palazuelos, J., Desai, B., Weisberg, I., Alfonso, F., Guzman, L. A., Hernandez-Antolin, R., Zenni, M. Z., Macaya, C. et al. (2008) Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb. Haemost. 99, 161-168
7. Bonello, L., Camoin-Jau, L., Armero, S., Com, O., Arques, S., Burignat-Bonello, C., Giacomoni, M. P., Bonello, R., Collet, F., Rossi, P. et al. (2009) Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am. J. Cardiol. 103, 5-10
8. Bonello, L., Camoin-Jau, L., Arques, S., Boyer, C., Panagides, D., Wittenberg, O., Simeoni, M. C., Barragan, P., Dignat-George, F. and Paganelli, F. (2008) Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404-1411
9. Siller-Matula, J. M. and Jilma, B. (2010) Ticagrelor: from discovery to clinical trial phase III. Future Cardiol. 6, 753-764
10. Schror, K., Siller-Matula, J. M. and Huber, K. (2012) Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundam. Clin. Pharmacol. 26, 39-46
11. Kozinski, M., Obonska, K., Stankowska, K., Navarese, E. P., Fabiszak, T., Stolarek, W., Kasprzak, M., Siller-Matula, J. M., Rosc, D., Kubica, J. and De Servi, S. (2014) Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol. J., doi:10.5603/CJ.a2014.0026
12. Kubica, J., Kozinski, M., Navarese, E. P., Tantry, U., Kubica, A., Siller-Matula, J. M., Jeong, Y. H., Fabiszak, T., Andruszkiewicz, A. and Gurbel, P. A. (2014) Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr. Med. Res. Opin. 30, 813-828
13. Siller-Matula, J. M., Francesconi, M., Dechant, C., Jilma, B., Maurer, G., Delle-Karth, G., Gouya, G., Ruzicka, K., Podczeck-Schweighofer, A. and Christ, G. (2013) Personalized antiplatelet treatment after percutaneous coronary intervention:the MADONNA study. Int. J. Cardiol. 167, 2018-2023
14. Siller-Matula, J. M. and Jilma, B. (2013) Why have studies of tailored anti-platelet therapy failed so far? Thromb. Haemost. 110, 628-631
15. Kozinski, M., Bielis, L., Wisniewska-Szmyt, J., Boinska, J., Stolarek, W., Marciniak, A., Kubica, A., Grabczewska, Z., Navarese, E. P., Andreotti, F. et al. (2011) Diurnal variation in platelet inhibition by clopidogrel. Platelets 22, 579-587
16. Kasprzak, M., Kozinski, M., Bielis, L., Boinska, J., Plazuk, W., Marciniak, A., Budzynski, J., Siller-Matula, J., Rosc, D. and Kubica, J. (2009) Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol. J. 16, 535-544
17. Mayr, F. B., Knobl, P., Jilma, B., Siller-Matula, J. M., Wagner, P. G., Schaub, R. G., Gilbert, J. C. and Jilma-Stohlawetz, P. (2010) The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion 50, 1079-1087
18. Spiel, A. O., Derhaschnig, U., Schwameis, M., Bartko, J., Siller-Matula, J. M. and Jilma, B. (2012) Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial. Clin. Sci. 123, 591-600
19. Siller-Matula, J. M., Delle-Karth, G., Christ, G., Neunteufl, T., Maurer, G., Huber, K., Tolios, A., Drucker, C. and Jilma, B. (2013) Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int. J. Cardiol. 167, 430-435
20. Siller-Matula, J. M., Christ, G., Lang, I. M., Delle-Karth, G., Huber, K. and Jilma, B. (2010) Multiple electrode aggregometry predicts stent thrombosis better than the VASP assay. J. Thromb. Haemost. 8, 351-359
21. Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schomig, A., Kastrati, A. and von Beckerath, N. (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll Cardiol. 53, 849-856
22. Siller-Matula, J. M., Delle-Karth, G., Lang, I. M., Neunteufl, T., Kozinski, M., Kubica, J., Maurer, G., Linkowska, K., Grzybowski, T., Huber, K. and Jilma, B. (2012) Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J. Thromb. Haemost. 10, 529-542
23. Toth, O., Calatzis, A., Penz, S., Losonczy, H. and Siess, W. (2006) Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb. Haemost. 96, 781-788
24. Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G. A., Steg, P. G., Morel, M. A., Mauri, L., Vranckx, P. et al. (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115, 2344-2351
25. Alpert, J. S., Thygesen, K., Jaffe, A. and White, H. D. (2008) The universal definition of myocardial infarction: a consensus document: ischaemic heart disease. Heart 94, 1335-1341
26. Steg, P. G., Huber, K., Andreotti, F., Arnesen, H., Atar, D., Badimon, L., Bassand, J. P., De Caterina, R., Eikelboom, J. A., Gulba, D. et al. (2011) Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J. 32, 1854-1864
27. Collet, J. P., Cuisset, T., Range, G., Cayla, G., Elhadad, S., Pouillot, C., Henry, P., Motreff, P., Carrie, D., Boueri, Z. et al. (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367, 2100-2109
28. Price, M. J., Berger, P. B., Teirstein, P. S., Tanguay, J. F., Angiolillo, D. J., Spriggs, D., Puri, S., Robbins, M., Garratt, K. N., Bertrand, O. F. et al. (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097-1105
29. Trenk, D., Stone, G. W., Gawaz, M., Kastrati, A., Angiolillo, D. J., Muller, U., Richardt, G., Jakubowski, J. A. and Neumann, F. J. (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J. Am. Coll. Cardiol. 59, 2159-2164
30. Siller-Matula, J. M. and Jilma, B. (2013) Why have studies of tailored anti-platelet therapy failed so far? Thromb. Haemost. 110, 628-631
31. Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J., Bal, E. T., Deneer, V. H., Harmsze, A. M., van der Heyden, J. A., Rensing, B. J. et al. (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303, 754-762
32. Bal Dit Sollier, C., Berge, N., Boval, B., Dubar, M. and Drouet, L. (2010) Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb. Haemost. 104, 571-581
33. Aradi, D., Tornyos, A., Pinter, T., Vorobcsuk, A., Konyi, A., Falukozy, J., Veress, G., Magyari, B., Horvath, I. G. and Komocsi, A. (2014) Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J. Am. Coll. Cardiol. 63, 1061-1070
34. Consuegra-Sanchez, L., Lopez-Palop, R., Cano, P., Carrillo, P., Pico, F., Villegas, M., Sanchis, J. and Kaski, J. C. (2013) Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays. J. Thromb. Haemost. 11, 379-381
35. Bonello, L., Pansieri, M., Mancini, J., Bonello, R., Maillard, L., Barnay, P., Rossi, P., Ait-Mokhtar, O., Jouve, B., Collet, F. et al. (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J. Am. Coll. Cardiol. 58, 467-473
36. Michelson, A. D., Frelinger, 3rd, A. L., Braunwald, E., Downey, W. E., Angiolillo, D. J., Xenopoulos, N. P., Jakubowski, J. A., Li, Y., Murphy, S. A., Qin, J. et al. (2009) Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J. 30, 1753-1763
37. Bonello, L., Mancini, J., Pansieri, M., Maillard, L., Rossi, P., Collet, F., Jouve, B., Wittenberg, O., Laine, M., Michelet, P. et al. (2012) Relationship between post-treatment platelet reactivity and ischemic and bleeding events at one year follow-up in patients receiving prasugrel. J. Thromb. Haemost. 10, 1999-2005
38. Alexopoulos, D., Xanthopoulou, I., Davlouros, P., Plakomyti, T. E., Panagiotou, A., Mavronasiou, E. and Hahalis, G. (2011) Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am. Heart J. 162, 733-739
39. Alexopoulos, D., Panagiotou, A., Xanthopoulou, I., Komninakis, D., Kassimis, G., Davlouros, P., Fourtounas, C. and Goumenos, D. (2011) Antiplatelet effects of prasugrel vs double clopidogrel in patients on hemodialysis and high on-treatment platelet reactivity. J. Thromb. Haemost. 9, 2379-2385
40. Alexopoulos, D., Xanthopoulou, I., Gkizas, V., Kassimis, G., Theodoropoulos, K. C., Makris, G., Koutsogiannis, N., Damelou, A., Tsigkas, G., Davlouros, P. and Hahalis, G. (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 5, 797-804
41. Parodi, G., Valenti, R., Bellandi, B., Migliorini, A., Marcucci, R., Comito, V., Carrabba, N., Santini, A., Gensini, G. F., Abbate, R. and Antoniucci, D. (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J. Am. Coll. Cardiol. 61, 1601-1606
42. Christ, G., Hafner, T., Siller-Matula, J. M., Francesconi, M., Grohs, K., Wilhelm, E. and Podczeck-Schweighofer, A. (2013) Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients:the blocking and bridging strategy. Thromb. Res. 132, e36-e41
43. Abtan, J., Silvain, J., Kerneis, M., O'Connor, S. A., Barthelemy, O., Vignalou, J. B., Beygui, F., Brugier, D., Collet, J. P. and Montalescot, G. (2013) Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. Thromb. Haemost. 110, 1055-1064
44. Stone, G. W., Witzenbichler, B., Weisz, G., Rinaldi, M. J., Neumann, F. J., Metzger, D. C., Henry, T. D., Cox, D. A., Duffy, P. L., Mazzaferri, E. et al. for the A-DESI (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382, 614-623
45. Stone, G. (2011) A large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after des implantation. Results from the ADAPT-DES study. J. Am. Coll. Cardiol. 58, (Suppl. B), XII
46. Gurbel, P. A., Becker, R. C., Mann, K. G., Steinhubl, S. R. and Michelson, A. D. (2007) Platelet function monitoring in patients with coronary artery disease. J. Am. Coll. Cardiol. 50, 1822-1834
47. Sibbing, D., Schulz, S., Braun, S., Morath, T., Stegherr, J., Mehilli, J., Schomig, A., von Beckerath, N. and Kastrati, A. (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J. Thromb. Haemost. 8, 250-256
48. Sibbing, D., Steinhubl, S. R., Schulz, S., Schomig, A. and Kastrati, A. (2010) Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients:initial evidence of a therapeutic window. J. Am. Coll. Cardiol. 56, 317-318
49. Campo, G., Parrinello, G., Ferraresi, P., Lunghi, B., Tebaldi, M., Miccoli, M., Marchesini, J., Bernardi, F., Ferrari, R. and Valgimigli, M. (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J. Am. Coll. Cardiol. 57, 2474-2483
50. Siller-Matula, J. M., Trenk, D., Krahenbuhl, S., Michelson, A. D. and Delle-Karth, G. (2014) Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J. Thromb. Haemost. 12, 2-13